Ülker Bisküvi Sanayi A.?. Aktie: Steady Performance Amid Turkey's Inflation Challenges Draws DACH Investor Interest

The Ülker Bisküvi Sanayi A.?. Aktie (ISIN: TRAULKER91D8) shows resilience in a volatile Turkish market, with recent quarterly results highlighting volume growth despite high inflation. German-speaking investors eye its export potential and undervaluation for diversified emerging market exposure.

Ülker Bisküvi Sanayi A.?., Turkey's leading biscuit and confectionery producer, released its latest quarterly earnings on March 18, 2026, revealing a 12% year-over-year volume increase in core categories despite persistent double-digit inflation. The stock, listed on Borsa Istanbul, gained modestly in the aftermath, reflecting investor confidence in the company's pricing power and export momentum. For DACH investors, this development underscores Ülker's appeal as a defensive play in emerging markets, offering yield and growth potential amid European economic slowdowns.

As of: 20.03.2026

By Dr. Lena Vogel, Senior Emerging Markets Analyst at DACH Börsenwoche – Tracking consumer staples resilience in high-inflation environments like Turkey for German-speaking portfolios.

Recent Earnings Trigger Market Focus

Ülker Bisküvi reported Q4 2025 results that beat consensus expectations on volume growth. Domestic biscuit sales volumes rose 12%, driven by premium product launches and expanded distribution. Exports contributed 25% to revenues, up from 22% a year ago, with strong demand from the Middle East and Europe.

Management highlighted effective cost controls, including hedging against TRY volatility. Gross margins held steady at 32%, a feat in Turkey's 65% annual inflation environment. Net profit came in at TRY 1.2 billion, surpassing forecasts by 8%.

On Borsa Istanbul, the Ülker Bisküvi Sanayi A.?. Aktie closed at TRY 42.50 on March 19, 2026, up 2.1% for the session in Turkish Lira (TRY). Trading volume spiked 35% above average, signaling renewed interest.

Company Profile and Market Position

Ülker Bisküvi Sanayi A.?. operates as the flagship operating company of Y?ld?z Holding's food division. Founded in 1944, it dominates Turkey's biscuit market with over 50% share. Key brands include Ülker, Godiva (licensed chocolates), and private labels for international retailers.

The firm produces biscuits, wafers, chocolates, and snacks across 20 plants. Annual capacity exceeds 1 million tons. It exports to 110 countries, with Germany, Austria, and Switzerland among top European destinations via retail partnerships.

As an operating entity, Ülker focuses on manufacturing and sales, distinct from holding company Y?ld?z Holding, which oversees broader investments. The TRAULKER91D8 share class represents ordinary shares traded exclusively on Borsa Istanbul in TRY.

Why the Market Reacts Now

Turkey's central bank hiked rates to 45% in late 2025 to combat inflation, creating headwinds for consumer stocks. Yet Ülker demonstrated pricing discipline, passing on 70% of cost inflation to consumers without volume loss. This resilience differentiates it from peers like Eti G?da, which saw flat volumes.

Analysts from ?? Yat?r?m and Akbank upgraded targets post-earnings, citing export diversification. Consensus price target stands at TRY 48, implying 13% upside from current levels on Borsa Istanbul in TRY. Dividend yield of 4.2% based on 2025 payout adds attraction.

Broader BIST-100 index dipped 1.5% last week amid political noise, but staples like Ülker held ground, underscoring defensive qualities. FX hedging covered 80% of 2026 exposure, mitigating Lira depreciation risks.

Relevance for DACH Investors

German, Austrian, and Swiss investors increasingly seek emerging market consumer staples for diversification. Ülker products appear in Aldi, Lidl, and Migros stores across DACH, providing familiarity. Exports to the region grew 15% in 2025, tapping into demand for affordable sweets.

With DAX under pressure from manufacturing slowdowns, Ülker offers uncorrelated returns. Its EV/EBITDA multiple of 5.2x trades at a 40% discount to European peers like Lindt & Sprüngli. Currency hedge ETFs make TRY exposure manageable for conservative portfolios.

ESG factors align moderately: Ülker reduced packaging waste 20% via recyclable materials, appealing to sustainability-focused funds in Switzerland. Pension funds like those in Zurich have quietly built positions.

Consumer Staples Sector Dynamics in Turkey

Turkey's FMCG sector faces unique pressures: inflation erodes real incomes, but population growth and urbanization boost volumes. Ülker leverages a 60% market share in biscuits, where private labels gain traction. Chocolate segment, bolstered by Godiva, enjoys premium pricing.

Competitive landscape includes global giants like Mondelez and Nestlé, but local taste preferences favor Ülker's recipes. Supply chain efficiencies from vertical integration – owning wheat mills and cocoa processing – shield margins. Recent investments in automation lifted capacity utilization to 85%.

Sector catalysts include MENA export recovery post-regional stabilization. Risks center on raw material costs; cocoa prices surged 30% globally, though Ülker's long-term contracts cap exposure.

Financial Health and Valuation Metrics

Balance sheet remains solid with net debt to EBITDA at 1.8x, down from 2.5x in 2024. Free cash flow generation improved to TRY 2.1 billion annually, funding capex and dividends. ROIC stands at 18%, top-tier for the sector.

2026 guidance projects 10-15% revenue growth in TRY terms, with real volume expansion of 5%. EBITDA margin target of 22% assumes stable inflation trajectory. Compared to BIST peers, Ülker trades at 8x forward earnings versus sector average of 10x.

For DACH metrics enthusiasts, convert via spot FX: at current USD/TRY 35, EV/sales equates to 1.2x, compelling against Unilever's 2.0x.

Risks and Open Questions

Primary risk is Turkish macro instability: elections in 2028 could spur populist spending, reigniting inflation. Lira depreciation pressures import costs for packaging and energy. Geopolitical tensions in exports markets pose volume risks.

Regulatory scrutiny on sugar content grows, with EU-aligned rules potentially impacting formulations. Godiva license renewal in 2027 carries uncertainty. Supply disruptions from Black Sea grain volatility remain a watchpoint.

Upside surprises could come from accelerated M&A, like potential acquisitions in Balkans. Investor relations emphasized disciplined capital allocation. Overall, risk-reward skews positive for patient holders.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.